EGFR and non-small cell lung carcinoma: These results indicate that upregulation of ELK1 contributes to the acquired resistance to EGFR-TKIs in NSCLC, and targeting ELK1 may represent an effective therapeutic strategy for restoring sensitivity to EGFR-TKIs in resistant tumors.